10058 and 10074 are Myc inhibitors that work by disrupting Myc/Max dimerization, and the activity of the two compounds in the PC3 human prostate cancer cell line was demonstrated by the significant inhibition of the mRNA expression of three (3) Myc target genes, CDC20, CDC25A, and CDC45 (Figure 1A). The gene discussed is MYC; the disease is prostate cancer.